phrykt

Dianthus Therapeutics, Inc. /DE/ (DNTH): who owns it and who trades it

As of Nov 16, 2026, DNTH insiders reported 70 open-market sales worth $75M and no purchases in the last 12 months, with 15% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marino Garcia (CEO), with $28M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Dianthus Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DNTH

265 funds and institutions reported DNTH shares worth $6.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 18.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)18.4%
BlackRock, Inc.9.3%
T. Rowe Price Investment Management, Inc.8.7%
Wellington Management Group LLP7.3%
Fairmount Funds Management LLC5.7%
T. Rowe Price Associates5.7%
State Street Corp5.3%
Vanguard Capital Management LLC4.9%
Avidity Partners Management LP4.7%
Octagon Capital Advisors LP4.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)8.20M18.44%$799M+6%
BlackRock, Inc.4.12M9.27%$402M+30%
T. Rowe Price Investment Management, Inc.3.89M8.74%$379M+201%
Wellington Management Group LLP3.23M7.26%$315M+24%
Fairmount Funds Management LLC2.54M5.71%$247MNo change
T. Rowe Price Associates2.51M5.66%$245M+119%
State Street Corp2.36M5.30%$230M+69%
Vanguard Capital Management LLC2.16M4.86%$211M+6%
Avidity Partners Management LP2.10M4.73%$205M-50%
Octagon Capital Advisors LP1.84M4.14%$180M-5%
TCG Crossover Management, LLC1.68M3.77%$163MNo change
Fred Alger Management, LLC1.30M2.93%$127M+12%
Geode Capital Management, LLC1.26M2.83%$123M+37%
Venrock Adviser, LLC1.18M2.65%$115MNo change
UBS Group AG1.14M2.56%$111M+46%
Deerfield Management Company, L.P.1.13M2.53%$110M+10%
Jennison Associates LLC1.02M2.30%$99.6M+111%
Polar Capital Holdings Plc1.02M2.29%$99.3M-5%
Citadel Advisors LLC974,9112.19%$95M-39%
Franklin Resources Inc968,9832.18%$94.5M+0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DNTH insiders reported $0 of open-market purchases and $75M of sales. 15% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$75M
70 trades, 8 people
Sales under a 10b5-1 plan
15%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 12, 2026

Purchases and sales by month

$28M$28MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Ryan SavitzCFOSale plan17,724$90.56$1.6MForm 4
Nov 11, 2026Ryan SavitzCFOSale plan3,044$90.03$274KForm 4
Nov 10, 2026Ryan SavitzCFOSale plan2,561$90.14$231KForm 4
Nov 9, 2026Ryan SavitzCFOSale plan300$85.16$25.5KForm 4
Nov 9, 2026Ryan SavitzCFOSale plan700$86.70$60.7KForm 4
Nov 9, 2026Ryan SavitzCFOSale plan1,736$88.84$154KForm 4
Nov 9, 2026Ryan SavitzCFOSale plan37,517$90.12$3.4MForm 4
Nov 9, 2026Ryan SavitzCFOSale plan58,396$90.90$5.3MForm 4
Nov 9, 2026Ryan SavitzCFOSale plan2,064$91.59$189KForm 4
Sep 17, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale7,928$100.43$796KForm 4
Sep 17, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale6,771$101.37$686KForm 4
Sep 17, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale3,501$102.39$358KForm 4
Sep 17, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale700$104.39$73.1KForm 4
Sep 17, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale1,100$103.20$114KForm 4
Sep 1, 2026Simrat RandhawaVice presidentSale2,600$105.19$273KForm 4
Sep 1, 2026Simrat RandhawaVice presidentSale7,215$106.25$767KForm 4
Sep 1, 2026Simrat RandhawaVice presidentSale13,309$106.74$1.4MForm 4
Aug 19, 2026Simon ReadDirectorSale2,778$117.55$327KForm 4
Aug 10, 2026Anne McGeorgeDirectorSale1,000$110.64$111KForm 4
Aug 10, 2026Anne McGeorgeDirectorSale700$111.41$78KForm 4
Aug 10, 2026Anne McGeorgeDirectorSale1,800$109.30$197KForm 4
Aug 10, 2026Anne McGeorgeDirectorSale2,800$108.38$303KForm 4
Aug 10, 2026Anne McGeorgeDirectorSale1,450$107.58$156KForm 4
Aug 10, 2026Simon ReadDirectorSale70$107.11$7.5KForm 4
Aug 10, 2026Simon ReadDirectorSale737$108.17$79.7KForm 4
Aug 10, 2026Simon ReadDirectorSale831$108.95$90.5KForm 4
Aug 10, 2026Simon ReadDirectorSale272$109.96$29.9KForm 4
Aug 10, 2026Simon ReadDirectorSale397$111.77$44.4KForm 4
Aug 10, 2026Simon ReadDirectorSale470$111.05$52.2KForm 4
Aug 10, 2026Adam M VenessVice presidentSale16,167$110.38$1.8MForm 4
Aug 7, 2026Adam M VenessVice presidentSale616$111.18$68.5KForm 4
Aug 7, 2026Adam M VenessVice presidentSale3,217$110.61$356KForm 4
Aug 7, 2026Marino GarciaCEOSale2,373$109.10$259KForm 4
Aug 7, 2026Marino GarciaCEOSale2,536$110.02$279KForm 4
Aug 7, 2026Marino GarciaCEOSale800$110.76$88.6KForm 4
Aug 7, 2026Marino GarciaCEOSale104,091$107.96$11.2MForm 4
Aug 7, 2026Marino GarciaCEOSale23,907$108.05$2.6MForm 4
Aug 7, 2026Marino GarciaCEOSale10,384$107.49$1.1MForm 4
Aug 7, 2026Marino GarciaCEOSale21,909$108.72$2.4MForm 4
Jul 9, 2026Ryan SavitzCFOSale10,354$100.22$1MForm 4
Jul 9, 2026Ryan SavitzCFOSale5,566$101.97$568KForm 4
Jul 9, 2026Ryan SavitzCFOSale15,329$101.24$1.6MForm 4
Jun 17, 2026Adam M VenessVice presidentSale13,229$81.38$1.1MForm 4
Jun 17, 2026Adam M VenessVice presidentSale16,771$80.34$1.3MForm 4
Jun 1, 2026Simrat RandhawaVice presidentSale16,943$90.72$1.5MForm 4
Jun 1, 2026Simrat RandhawaVice presidentSale4,159$91.37$380KForm 4
Jun 1, 2026Simrat RandhawaVice presidentSale5,428$89.72$487KForm 4
May 8, 2026Paula SoteropoulosDirectorSale599$85.47$51.2KForm 4
Apr 9, 2026Ryan SavitzCFOSale8,224$89.84$739KForm 4
Mar 31, 2026Ryan SavitzCFOSale21,825$78.86$1.7MForm 4
Mar 31, 2026Ryan SavitzCFOSale1,485$80.25$119KForm 4
Mar 31, 2026Ryan SavitzCFOSale800$81.36$65.1KForm 4
Mar 31, 2026Ryan SavitzCFOSale2,366$82.84$196KForm 4
Mar 31, 2026Ryan SavitzCFOSale59,800$83.90$5MForm 4
Mar 31, 2026Ryan SavitzCFOSale19,469$84.57$1.6MForm 4
Mar 31, 2026Ryan SavitzCFOSale7,232$85.54$619KForm 4
Mar 31, 2026Ryan SavitzCFOSale1,390$78.33$109KForm 4
Mar 31, 2026Paula SoteropoulosDirectorSale599$80.11$48KForm 4
Mar 24, 2026Paula SoteropoulosDirectorSale27,594$78.05$2.2MForm 4
Mar 12, 2026Marino GarciaCEOSale65,517$81.74$5.4MForm 4
Mar 12, 2026Marino GarciaCEOSale43,505$80.69$3.5MForm 4
Mar 12, 2026Marino GarciaCEOSale12,796$82.60$1.1MForm 4
Mar 12, 2026Marino GarciaCEOSale200$83.38$16.7KForm 4
Mar 12, 2026Marino GarciaCEOSale900$85.53$77KForm 4
Mar 12, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale15,852$80.71$1.3MForm 4
Mar 12, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale300$85.53$25.7KForm 4
Mar 12, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale3,865$82.66$319KForm 4
Mar 12, 2026Edward CarrCHIEF ACCOUNTING OFFICERSale23,465$81.75$1.9MForm 4
Mar 12, 2026Simrat RandhawaVice presidentSale33,830$81.48$2.8MForm 4
Dec 4, 2025Ryan SavitzCFOSale20,000$45.18$904KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Marino GarciaCEO AND PRESIDENT, Director–$28MAug 7, 2026
Ryan SavitzCFO & CBO–$25.5MNov 12, 2026
Simrat RandhawaEVP, Head of R&D–$7.6MSep 1, 2026
Edward CarrCHIEF ACCOUNTING OFFICER–$5.6MSep 17, 2026
Adam M VenessSVP, General Counsel and Sec.–$4.6MAug 10, 2026
Paula SoteropoulosDirector–$2.3MMay 8, 2026
Anne McGeorgeDirector–$845KAug 10, 2026
Simon ReadDirector–$631KAug 19, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DNTH short interest

High short interest. 16.6% of DNTH shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 44%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.28M DNTH shares were sold short, 16.6% of the shares outstanding, up 3.2% from the report before. At the average daily volume of 914,517 shares, buying them all back would take about 10.1 trading days (days to cover).

Shares short, % of all shares

16.6%May 15Oct 3022.5%

Days to cover

10.1May 15Oct 3016.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.28M16.59%+3%914,51710.1
Oct 15, 20268.99M16.07%-2%883,43210.2
Sep 30, 20269.14M16.34%+4%1.10M8.3
Sep 15, 20268.83M15.79%+5%612,11914.4
Aug 31, 20268.43M15.07%+0%550,76015.3
Aug 14, 20268.42M15.05%+0%729,43611.5
Jul 31, 20268.38M18.84%-9%882,8729.5
Jul 15, 20269.22M20.73%-3%1.04M8.9
Jun 30, 20269.53M21.44%+37%1.74M5.5
Jun 15, 20266.98M15.69%+4%1.23M5.7
May 29, 20266.69M15.04%+4%615,01010.9
May 15, 20266.43M14.46%-2%450,63514.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Dianthus Therapeutics company events

Dianthus Therapeutics filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jun 12, 2026AnnouncementDianthus Therapeutics, Inc. posted an updated corporate presentation on the investor relations section of its website, which included the following interim responder analysis data for the first 40 patients that completed Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory… Filing
  4. May 22, 2026VoteReported shareholder vote results. Filing
  5. May 5, 2026ResultsReleased financial results. Filing
  6. Mar 26, 2026AnnouncementDianthus Therapeutics, Inc. posted an updated corporate presentation on the investor relations section of its website. Filing
  7. Mar 12, 2026AgreementDianthus Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named therein, to issue and sell 7,313,582… Filing
  8. Mar 9, 2026AnnouncementThe Company made publicly available a data presentation announcing early GO decision following interim responder analysis in Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy on the investor relations section of its website. Filing
  9. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Dianthus Therapeutics financials

Famous investors that hold DNTH

5 of the 50 well-known investors we track reported holding DNTH in their latest 13F filing. The largest position is Ken Griffin's, worth $55.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026629,225$55.4M0.0%-35%
Steve Cohen · Point72 Asset ManagementQ3 2026290,622$25.6M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 2026272,863$24M0.0%+1068%
Israel Englander · Millennium ManagementQ3 2026211,586$18.6M0.0%+130%
Paul Tudor Jones · Tudor Investment CorpQ3 202693,353$8.2M0.0%+150%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DNTH in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G/A10.5%
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G/A10.5%
Oct 30, 2026Vanguard Capital Management13G5.1%
Oct 30, 2026Vanguard Capital Management13G5.1%

Questions about Dianthus Therapeutics, Inc. /DE/ (DNTH) stock

Who owns the most DNTH stock?

The largest reported owner of Dianthus Therapeutics, Inc. /DE/ (DNTH) is FMR LLC (Fidelity), with 18.4% of the company. In total, 265 funds and institutions reported holding DNTH at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are DNTH insiders buying or selling?

In the last 12 months, DNTH insiders reported no open-market purchases and 70 sales worth $75M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in DNTH?

As of Oct 30, 2026, 9.28M DNTH shares were sold short, 16.6% of the shares outstanding, up 3.2% from the report before. At the average daily volume of 914,517 shares, buying them all back would take about 10.1 trading days (days to cover). See the history.

Which famous investors hold DNTH?

5 of the 50 well-known investors we track reported DNTH in their latest 13F filing, including Ken Griffin, Steve Cohen, Ken Fisher. The largest position is worth $55.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.